Company profile
Zymeworks Inc.
NASDAQ:ZYMEBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03821233 | phase1 | completed | 2019-04-15 | 2024-09-27 | Zymeworks BC Inc. | A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers |
| NCT06523803 | phase1 | terminated | 2024-09-30 | 2025-09-30 | Zymeworks BC Inc. | A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers |
| NCT06555744 | phase1 | active_not_recruiting | 2024-10-30 | 2026-12-01 | Zymeworks BC Inc. | A Study of ZW191 in Participants With Solid Tumors |
| NCT07164313 | phase1 | recruiting | 2025-10-21 | 2027-09-01 | Zymeworks BC Inc. | A Study of ZW251 in Participants With Advanced Solid Tumors |
FDA applications (0)
No records yet.